ofloxacin has been researched along with Nervous System Disorders in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The areas under the concentration-time curves during the 12-h dosing interval (AUC(0-tau)s) were 47." | 1.32 | Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. ( Benetton, C; Furlanut, M; Nascimben, E; Pavan, F; Pea, F; Scotton, PG; Vaglia, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pea, F | 1 |
| Pavan, F | 1 |
| Nascimben, E | 1 |
| Benetton, C | 1 |
| Scotton, PG | 1 |
| Vaglia, A | 1 |
| Furlanut, M | 1 |
| Jüngst, G | 1 |
| Mohr, R | 1 |
1 trial available for ofloxacin and Nervous System Disorders
| Article | Year |
|---|---|
Side effects of ofloxacin in clinical trials and in postmarketing surveillance.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Drug Hypersensitivity; Evaluation Studies as Topic; | 1987 |
1 other study available for ofloxacin and Nervous System Disorders
| Article | Year |
|---|---|
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.
Topics: Adult; Aged; Area Under Curve; Cohort Studies; Drug Therapy, Combination; Female; Glucose; Half-Life | 2003 |